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ABSTRACT Deregulated activation of RAS/extracellular signal-regulated kinase (ERK)
signaling and defects in retinoic acid receptor (RAR) signaling are both implicated in
many types of cancers. However, interrelationships between these alterations in reg-
ulating cancer cell fates have not been fully elucidated. Here, we show that RAS/ERK
and RAR signaling pathways antagonistically interact with each other to regulate
colorectal cancer (CRC) cell fates. We show that RAR signaling activation promotes
spontaneous differentiation of CRC cells, while ERK activation suppresses it. Our mi-
croarray analyses identify genes whose expression levels are upregulated by RAR
signaling. Notably, one of these genes, MKP4, encoding a member of dual-speciﬁcity
phosphatases for mitogen-activated protein (MAP) kinases, mediates ERK inactivation
upon RAR activation, thereby promoting the differentiation of CRC cells. Moreover,
our results also show that RA induction of RAR target genes is suppressed by the
ERK pathway activation. This suppression results from the inhibition of RAR tran-
scriptional activity, which is shown to be mediated through an RIP140/histone
deacetylase (HDAC)-mediated mechanism. These results identify antagonistic interac-
tions between RAS/ERK and RAR signaling in the cell fate decision of CRC cells and
deﬁne their underlying molecular mechanisms.
KEYWORDS ERK MAP kinase, colorectal cancer, retinoic acid receptor
Retinoic acid (RA), an active derivative of vitamin A, plays an important role in thedevelopment and homeostasis of many vertebrate tissues through its regulatory
effects on cell proliferation, differentiation, and apoptosis. Most of these effects are
mediated by nuclear retinoid receptors, RA receptors (RARs), and retinoid X receptors
(RXRs) (1, 2). The basic mechanism of RAR/RXR-mediated transcriptional regulation
relies on the ability of RAR/RXR to recruit transcriptional corepressors and coactivators
and involves a series of steps, as follows (2–4). (i) In the absence of ligand, RAR
associates with the corepressor complex that mediates transrepression by the recruit-
ment of histone deacetylase (HDAC). (ii) Ligand binding to RAR causes the dissociation
of the corepressor complex and the recruitment of the coactivator complexes, which
contain histone acetyltransferase, methyltransferase, and kinase and/or ATP-dependent
chromatin remodeling activities that decompact repressive chromatin. (iii) Then, the
coactivators dissociate, and the mediator complex assembles to recruit RNA polymer-
ase II and the general transcription factors to the promoter, resulting in transcriptional
initiation.
Transactivation of RAR target genes often induces cell proliferation arrest, cell
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differentiation, and apoptosis in a wide variety of biological processes. Consequently,
retinoids have tumor-suppressive activity, and loss of normal RAR function in the
presence of physiological levels of RA is associated with the progression of a diverse
range of cancers. In the case of acute promyelocytic leukemia (APL), chromosomal
translocation generates the PML-RAR fusion gene that suppresses normal RAR func-
tions (5–7). Administration of RA causes degradation of PML-RAR and restores normal
RAR activity, which induces differentiation of leukemia cells and complete remission of
APL (8). Retinoids also show suppressive effects on various solid tumors, including
breast, lung, and colorectal carcinomas (3, 4, 8). For instance, previous studies have
shown that RA-induced expression of RAR promotes differentiation and apoptosis of
several types of cancer cells (9). It has been also shown that RA promotes differentiation
of intestinal tumor (adenoma) cells through inducing expression of HOXA5 (10). Despite
a large number of reports, however, entire mechanisms by which RAR signaling exerts
tumor-suppressive effects on many types of tumor have remained elusive. In addition,
it has also remained unclear how normal RAR function is abolished during progression
of these tumors.
Among genetic mutations that frequently occur in many solid tumors are those in
the RAS and RAF genes (11–14). In colorectal cancers (CRCs), K-RAS or B-RAF mutations
usually occur following the adenomatous polyposis coli gene mutations, the earliest
genetic mutations found in colorectal tumorigenesis, and promote tumor progression
(15–20). RAS/RAF mutations cause constitutive activation of downstream ERK/mitogen-
activated protein (MAP) kinase signaling, which plays a critical role in cell proliferation
(21). Thus, deregulated activation of RAS/RAF/ERK signaling and defects in RAR signal-
ing are both characteristics of many solid cancers. However, it remains elusive whether
there are any causal relationships between these alterations in many cancers.
In this study, we investigated a role of RAR signaling in regulating differentiation of
CRC cells. We show that RAR signaling is enhanced during the spontaneous differen-
tiation of Caco-2 CRC cells and that the enhanced RAR signaling promotes the differ-
entiation. Our microarray analyses identify genes whose expression levels are regulated
by RAR signaling. Remarkably, RAR signaling causes a reduction in ERK activity by
inducing MAP kinase phosphatase 4 (MKP4), thereby promoting differentiation. More-
over, our results show that RA-induced upregulation of the downstream target genes
of RAR signaling is suppressed by ERK activation through an RIP140/HDAC-mediated
mechanism. Thus, RAR signaling and ERK signaling interact antagonistically to regulate
the differentiation of CRC cells.
RESULTS
RAR signaling promotes the spontaneous differentiation of CRC cells. To inves-
tigate a mechanism by which RAR signaling exerts tumor-suppressive activity on CRC
cells, we ﬁrst examined the potential involvement of RAR signaling in the differentiation
of CRC cells. As a model system for differentiation, we used Caco-2 CRC cells, which
spontaneously differentiate into enterocytes upon reaching conﬂuence (22). In fact, a
molecular marker for enterocytic differentiation, sucrase-isomaltase (SI), was induced to
be expressed after conﬂuence (see below). We then investigated the expression levels
of RAR, a well-known transcriptional target gene of RAR itself. Both the mRNA level
and the protein level of RAR were found to be dramatically increased during differ-
entiation (Fig. 1A and B). We then examined whether RAR induction during differen-
tiation was RAR dependent. To this end, we used the dominant negative form of RAR
(RAR-DN), which lacks the C terminus ligand-binding domain. This RAR-DN does not
have transactivation activity but is able to bind to the RA-responsive element (RARE),
thereby competing with endogenous RARs for binding to the target promoters. In fact,
RARE-dependent transcription of a reporter gene is suppressed by the expression of
RAR-DN (Fig. 1C). The stable expression of RAR-DN suppressed RAR induction
during the differentiation of Caco-2 cells (Fig. 1D), suggesting that RAR is induced by
RAR during differentiation. Consistent with this, treatment with a synthetic RAR antag-
onist, LE540, was also found to suppress RAR induction (Fig. 1E). The inhibitory effect
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of LE540 was canceled by RA (Fig. 1E), conﬁrming the speciﬁc action of LE540 on RAR.
These results suggest that RAR signaling is activated during the differentiation of CRC
cells.
We treated Caco-2 cells with RA or the RAR antagonist LE540 to examine the
importance of RA signaling for CRC cell differentiation. Consistent with ﬁndings of a
previous report (23), RA treatment promoted markedly the differentiation of Caco-2
RARβ
α-tubulin



















































LE540 + RA (1 nM)

















- + + +

























0 2 62 4 8(days)
HA
α-tubulin




























FIG 1 RAR signaling promotes the differentiation of CRC cells. (A and B) The expression levels of RAR mRNA (A)
and protein (B) were evaluated in differentiating Caco-2 cells. Cells were incubated for the indicated days after
reaching conﬂuence at day zero. (C) Transcriptional activation of a reporter plasmid expressing luciferase under the
control of the RAREs (RARE3-Luc) was evaluated in Caco-2 cells transfected with empty vectors or with expression
plasmids for the dominant negative form of RAR (RAR-DN). Cells were treated with 100 nM RA for 12 h prior to
the measurements (means  standard errors of the means; n  4). (D) Caco-2 cells were infected with a lentivirus
expressing the HA-tagged wild-type (WT) or dominant negative form of RAR (DN) 2 days before conﬂuence
(day 2). Cell lysates were prepared at the indicated time points and analyzed by immunoblotting. (E to G) Caco-2
cells were treated with vehicle, RA (1 nM), LE540 (100 nM), or retinol (ROH) for the indicated days after reaching
conﬂuence (day 0), and the expression levels of the indicated mRNAs were analyzed by RT-PCR. Values in bar
graphs are means  standard errors of the means at day 6 (n  3). *, P  0.05, for differences in results from rom
control samples (vehicle) or between indicated samples (Student’s t test).
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cells (Fig. 1F). LE540 treatment signiﬁcantly suppressed differentiation (Fig. 1F). RA
treatment cancelled the differentiation-suppressing effect of the RAR antagonist LE540
in a dose-dependent manner (Fig. 1F), conﬁrming the speciﬁcity of the action of LE540.
Moreover, treatment of cells with retinol, a precursor of RA, was found to enhance RAR
expression and promote differentiation in a dose-dependent manner (Fig. 1G). All of
these results demonstrated that RAR signaling is enhanced during the differentiation of
CRC cells and that the increased RAR signaling promotes differentiation.
Identiﬁcation of gene expression programs regulated by RAR signaling in CRC
cells. To further understand the role of RAR signaling in CRC cells, we have undertaken
a large-scale analysis of gene expression proﬁles by using microarrays (Fig. 2A). We
identiﬁed 41 probe sets (containing 34 genes) whose expression levels in RA-treated
cells were upregulated by more than 1.5-fold compared to levels in vehicle-treated cells
with statistical signiﬁcance in replicate experiments (Fig. 2B). Quantitative reverse
transcription-PCR (RT-PCR) analysis conﬁrmed the induction of most of these genes by
RA treatment (32 out of 34 genes) (Fig. 2C; see also Fig. S1 in the supplemental
material). To examine whether the induction of these RA-responsive genes is mediated
by RAR, we ﬁrst used RAR-speciﬁc agonists, Ch55 and Am580. The results show that all
of the 32 upregulated genes were induced by these agonists in a dose-dependent
manner (Fig. 2C and S1), suggesting that RAR mediates the RA-induced upregulation of
the expression of these genes. We then examined whether the expression of these
RA-responsive genes was dependent on transactivation activity of RAR by using the
dominant negative form of RAR (RAR-DN). The results showed that the expression of
RAR-DN suppresses RA induction of almost all the RA-responsive genes (30 out of 32
genes) (Fig. 2D and S2). We thus identiﬁed these genes as downstream transcriptional
targets of RAR signaling in CRC cells (Table S1). It has previously been shown that two
genes (i.e., CA2 and RARRES1) are expressed strongly in terminally differentiated cells of
normal mucosal tissues and adenoma tissues but are absent from poorly differentiated
CRC cells (24, 25). These observations are in good agreement with our results that RAR
signaling is activated during the differentiation of CRC cells (Fig. 1A to E).
RAR promotes MKP4 expression through directly binding to its promoter
region. Among the identiﬁed target genes of RAR signaling, we noticed that the MAP
kinase phosphatase 4 gene (MKP4) as it was one of the most strongly upregulated
genes (second most upregulated upon treatment with 100 nM RA) (Fig. 2C), and its
induction by RA was strongly suppressed by expression of RAR-DN (Fig. 2D). Since
MKP4 is a phosphatase speciﬁc for ERK MAP kinases (26, 27) that often play a crucial
role in controlling cell proliferation and differentiation, we considered that induction of
MKP4 by RA might have some effects on the differentiation of colorectal cancer cells.
Quantitative RT-PCR analysis showed that the mRNA level of MKP4 was gradually
increased upon treatment with RA (Fig. 3A). Consistent with the increased mRNA level,
the protein level of MKP4 was also increased by treatment with RA or an RAR agonist
(Fig. 3B). The expression of other members of the MKPs was not affected by RA
treatment (Fig. S3). RA treatment also increased the expression levels of MKP4 in HT29
and HeLa cells (Fig. 3C). These results suggest that RAR signaling promotes the
expression of MKP4 in these cells.
To examine whether MKP4 is a direct transcriptional target of RAR and RXR, we
searched the ﬁrst 1,000 bp of the MKP4 promoter region for a putative RA-responsive
element. We found an inverted direct repeat separated by 1 bp (DR1), which was shown
to be a consensus sequence for the RAR/RXR heterodimer, within the MKP4 promoter
region (177 to 165) (Fig. 3D). Then, a reporter assay with constructs expressing
luciferase (Luc) under the control of 60-bp fragments of the MKP4 promoter (200
to 141) containing either the wild-type (WT) or the mutated (4CG) DR1 element, in
which residues at positions 174C, 173C, 167C, and 166C were replaced by G,
was performed to examine the importance of this DR1 element. Treatment with RA or
the synthetic RAR agonist Ch55 signiﬁcantly increased the activity of the MKP4 pro-
moter containing the wild-type DR1 but not the mutated (4CG) DR1 in cells transfected
with both RAR and RXR (Fig. 3D). The effect of RA was speciﬁc to the DR1 element
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FIG 2 Identiﬁcation of downstream target genes of RAR signaling in CRC cells. (A) Schematic represen-
tation of the strategy to identify downstream target genes of RAR signaling. We ﬁrst performed microarray
experiments to identify genes whose expression levels were upregulated by RA treatment in Caco-2 cells.
Then, the effects of RAR agonists and dominant negative RAR on the expression levels of the identiﬁed
upregulated genes were investigated to examine whether expression of these genes is indeed regulated
by RAR. (B) Expression proﬁles of RA-dependently upregulated genes are shown. Cells were treated with
DMSO or RA (100 nM) for 24 h. Each horizontal line displays the expression data for one gene, where the
ratio of the mRNA level to its level in the control cells (DMSO) is represented by color according to the
color scale. (C) Conﬂuent Caco-2 cells were treated with RA, Ch55, or Am580 for 24 h. The mRNA levels
of the RA-dependently upregulated genes were analyzed by RT-PCR. Data shown are relative mRNA levels
compared to those in control (vehicle-treated) cells (set to 1). The data of individual genes are ranked from
left to right according to the fold increase induced by treatment with 100 nM RA. Note that the expression
levels of only the top 10 genes among the upregulated genes are shown in this graph. The expression
levels of the remaining genes are shown in Fig. S1. *, P  0.05, for differences in results from those of the
control group (vehicle) (Student’s t test). (D) Caco-2 cells were infected with the lentivirus expressing
wild-type (WT) or a dominant negative form of RAR (DN). At 48 h after infection, cells were treated with
DMSO, RA (100 nM), or Ch55 (1 nM) and incubated for 24 h. Total RNA was prepared and analyzed by
RT-PCR. The data of individual genes are ranked as described for panel C. Note that the expression levels
of only 10 genes among the upregulated genes are shown in this graph. The expression levels of the
remaining genes are shown in Fig. S2. Values shown in panels C and D are means  standard errors of
the means (n  3). *, P  0.05 (Student’s t test).
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because RA did not show any activity on the parental pGL3 reporter in cells transfected
with both RAR and RXR (Fig. S4A). Moreover, treatment with the RAR antagonist
LE540 inhibited the RA-induced activation of the DR1 element (Fig. S4B). These results
suggest that transcriptional activity of this DR1 element is regulated by the RAR/RXR
complex. We then examined whether RAR and RXR could bind directly to this DR1
element by DNA pulldown assay. We found that Flag-tagged RAR and hemagglutinin
(HA)-tagged RXR expressed in HEK293 cells were precipitated with biotinylated
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FIG 3 RAR promotes MKP4 expression through directly binding to its promoter region. (A and B) The
mRNA and protein levels of MKP4 in Caco-2 cells treated with DMSO (ﬁlled squares), 100 nM RA (open
squares), or 100 nM Ch55 were analyzed by RT-PCR (A) and immunoblotting (B), respectively. Data shown
are representative of two independent experiments. (C) HeLa and HT29 cells were treated with 100 nM
RA for 24 h or 1 M RA for 3 days, respectively. The MKP4 mRNA levels were analyzed by RT-PCR
(means  standard errors of the means; HT29 cell experiments, n  3; HeLa cell experiments, n  4). *,
P 0.01. (D) Transcriptional activation of reporter plasmids expressing luciferase under the control of the
MKP4 promoter containing a wild-type (WT) or mutated (4CG) DR1 element was evaluated in Caco-2 cells
transfected with empty vectors or with expression plasmids for RAR and RXR. Cells were treated with
1 M RA or Ch55 for 36 h prior to the measurements (means  standard errors of the means; n  3).
*, P  0.01. (E and F) Lysates from HEK293 cells transfected with empty vectors or with expression
plasmids for RAR and RXR (E) and lysates from Caco-2 cells treated with 100 nM RA for 36 h (F) were
subjected to DNA pulldown assays with biotinylated oligonucleotides corresponding to 60-bp fragments
(200 to 141) of the MKP4 promoter containing the WT or the mutated (4CG) DR1 and analyzed by
immunoblotting. (G) Chromatin fragments were prepared from Caco-2 cells stably expressing myc-
tagged RAR or enhanced green ﬂuorescent protein (EGFP) and subjected to ChIP analyses with the
indicated antibodies. Values are means  standard errors of the means from two or three experiments.
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oligonucleotides corresponding to 60-bp fragments (200 to 141) of the MKP4
promoter containing the wild-type (WT) but not the mutated (4CG) DR1 (Fig. 3E).
Moreover, endogenous RAR and RAR were also precipitated from Caco-2 cell lysates
by oligonucleotides in an intact DR1 element-dependent manner (Fig. 3F), suggesting
that the RAR/RXR heterodimer could directly bind to this DR1 element. Finally, we
examined whether RAR binds to the MKP4 promoter in vivo by chromatin immuno-
precipitation (ChIP) experiments. The results demonstrated the speciﬁc binding of
RAR to the MKP4 promoter (Fig. 3G). These results, taken together, show that
RA-induced transactivation of RAR directly upregulates the MKP4 expression level
through this DR1 element.
RAR signaling inactivates ERK through induction of MKP4 during the differen-
tiation of CRC cells. We then examined whether MKP4 is involved in RAR signaling-
induced differentiation of CRC cells. We found that the expression level of MKP4 was
gradually increased during the differentiation of Caco-2 cells at both the mRNA and the
protein levels (Fig. 4A and B). This was likely due to the increase in RAR activity during
differentiation (Fig. 1A) as treatment with an RAR-speciﬁc antagonist, LE540, sup-
pressed the increase in MKP4 expression (Fig. 4A and B). The effect of LE540 was
cancelled by the addition of RA, indicating again the speciﬁcity of the action of the RAR
antagonist LE540 (Fig. 4A). Moreover, treatment with RA promoted an increase in MKP4
expression during differentiation (Fig. 4A and B). These results suggest that RAR
signaling promotes MKP4 expression during the differentiation of CRC cells. Consistent
with the increase in the MKP4 expression level, ERK activity was gradually decreased
during differentiation (Fig. 4B). Remarkably, RA treatment promoted ERK inactivation
during differentiation, whereas LE540 treatment suppressed it (Fig. 4B). Thus, the
increase in the MKP4 protein level was inversely correlated with the phosphorylation
level of ERK. Importantly, however, the state of MEK activation was not changed
signiﬁcantly by RA or LE540 treatment (Fig. 4B), suggesting that RAR signaling sup-
presses ERK without affecting MEK during differentiation.
We then examined the role of MKP4 in ERK inactivation during differentiation. To
this end, we inhibited MKP4 expression by a small interfering RNA (siRNA). Our MKP4
siRNA suppressed MKP4 expression by about 70% at the protein level (Fig. 4C). Since
the effects of transfected siRNAs were gradually weakened by degradation and also
since MKP4 expression was promoted by endogenous RAR signaling during differen-
tiation, the MKP4 protein level was gradually upregulated even in cells transfected with
the MKP4 siRNA (Fig. 4C). In these cells, however, the MKP4 protein level was still
signiﬁcantly lower than that in the control cells that were transfected with the control
siRNA and treated similarly for the same days (Fig. 4C). The suppression of MKP4
signiﬁcantly inhibited the reduction in ERK activity in both the absence and presence
of RA (Fig. 4C). The state of MEK activation was not affected by either the MKP4 siRNA
or retinoic acid (Fig. 4C). Although overexpressed MKP4 was previously reported to be
able to inhibit both ERK and p38 MAP kinase (27), downregulation of MKP4 in Caco-2
cells affected only ERK activation and did not affect p38 activation (Fig. 4C). These
results suggest that RAR signaling suppresses ERK activity without affecting MEK by
inducing expression of MKP4. Importantly, however, the increase in the MKP4 protein
level and the decrease in the phosphorylation level of ERK were not completely
matched when samples cultured for different numbers of days were compared (Fig. 4C).
Indeed, ERK activity was slightly decreased over the time course, independently of
MKP4 expression (Fig. 4C, 2nd lane versus 11th lane). We thus think that the contri-
bution of MKP4 to ERK inactivation during differentiation is partial and that there might
be other, additional mechanisms responsible for ERK inactivation.
To conﬁrm the speciﬁcity of the effect of the MKP4 knockdown, we then performed
rescue experiments by using HA-tagged mouse MKP4, which is resistant to the MKP4
siRNA. MKP4 knockdown by siRNA suppressed the RA-promoted inhibition of ERK (Fig.
4D). In cells expressing mouse MKP4, however, the inhibition of ERK occurred (Fig. 4D).
These results clearly indicate that the reduction in ERK activity occurs, at least in part,
through MKP4 upregulation during the differentiation of CRC cells.
Antagonism between ERK and RAR Signaling in CRC Cells Molecular and Cellular Biology
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MKP4 mediates the differentiation-promoting effect of RAR signaling in CRC
cells. To assess the role of the reduction in ERK activity during differentiation of CRC
cells, we examined the effect of constitutive activation of ERK on differentiation. To this
end, we infected Caco-2 cells with an adenovirus which expresses constitutively active
MEK. In the infected cells, ERK was constitutively activated 10 h after infection (Fig. 5A),
and differentiation was almost completely suppressed (Fig. 5B). Therefore, inhibition of
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FIG 4 RAR signaling causes ERK inactivation through induction of MKP4 during the differentiation of CRC cells. (A and B)
Caco-2 cells were treated as described in the legend to Fig. 1F. Total mRNA and cell lysates were analyzed by RT-PCR (A) and
immunoblotting (B), respectively. Values in bar graphs are means  standard errors of the means at day 6 (n  3). *, P  0.05,
for differences in results from those of control samples (vehicle) or between indicated samples (Student’s t test). (C) Caco-2 cells
were transfected with an siRNA speciﬁc for MKP4 or a control siRNA 2 days before conﬂuence (day2). Then, cells were treated
with DMSO vehicle or 10 nM RA after reaching conﬂuence (day 0). Cell lysates were prepared and analyzed by immunoblotting.
The data for MKP4 represent two distinct blots of the same samples taken by short or long exposure. (D) Caco-2 cells were
transfected with the siRNAs as described for panel C. The next day, cells were infected with a control lentivirus or the virus
expressing HA-tagged mouse MKP4. From 24 h after infection, cells were treated with DMSO or RA (100 nM) for 48 h. Cell
lysates were prepared and analyzed by immunoblotting.
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Previous studies have revealed the involvement of several transcription factors in
the differentiation of normal intestinal epithelial cells and CRC cells. Sox9 and c-Myc,
which are subject to regulation by the Wnt signaling pathway, have been shown to be
important for the proliferative/undifferentiated phenotypes in both normal intestinal
epithelial cells and CRC cells (24, 28, 29). In contrast, Cdx2, which is expressed in
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FIG 5 ERK inactivation caused by RAR-dependent upregulation of MKP4 promotes the differentiation of CRC cells. (A to C)
Caco-2 cells were infected with an adenovirus expressing constitutively active MEK (caMEK) or a control virus (vector).
Lysates and total RNA were prepared and analyzed by immunoblotting (A) and RT-PCR (B and C), respectively. Values in bar
graphs are means  standard errors of the means at day 6 (n  3). *, P  0.05. (D) Cells were infected with the virus
expressing constitutively active MEK or a control virus as described for panel A. At 24 h postinfection, total RNA was
prepared and analyzed by RT-PCR (means  standard errors of the means; n  4). *, P  0.05. (E) Preconﬂuent Caco-2 cells
were treated with an MEK-speciﬁc inhibitor, U0126 (10 M), or DMSO vehicle for 24 h. Total RNA and cell lysates were
analyzed by RT-PCR (means  standard errors of the means; n  9) and immunoblotting, respectively. *, P  0.05. (F)
Caco-2 cells were treated as described in the legend to Fig. 4C. Cells were transfected with an siRNA speciﬁc for MKP4
or a control siRNA 2 days before conﬂuence (day 2) and then treated with DMSO vehicle or 10 nM RA after reaching
conﬂuence (day 0). The data conﬁrming the reduction of the MKP4 protein was shown in Fig. 4C. Total RNA was
prepared and analyzed by RT-PCR (means  standard errors of the means; n  3). *, P  0.05.
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differentiated villus cells, was shown to be essential for differentiation (30–32). We then
examined the effect of activation or inhibition of ERK on the expression of these
transcription factors. ERK activation by the expression of constitutively active MEK
rapidly induced the upregulation of Sox9 and c-Myc expression and the downregula-
tion of Cdx2 expression (Fig. 5C and D). The inhibition of ERK by treatment with the
speciﬁc MEK inhibitor U0126 induced the reverse effect: the expression levels of Sox9
and c-Myc were decreased, and the Cdx2 level was increased in preconﬂuent/undif-
ferentiated Caco-2 cells (Fig. 5E). As a result, the expression of the differentiation marker
SI was increased (Fig. 5E). Thus, ERK activity regulates the expression of these tran-
scription factors, and ERK inhibition induces changes in their expression proﬁles which
are similar to those in the physiological differentiation of intestinal epithelial cells.
We then inquired whether MKP4, which mediates ERK inactivation induced by RAR
signaling, is required for the differentiation of CRC cells. The siRNA-mediated knock-
down of MKP4 signiﬁcantly retarded the differentiation of Caco-2 cells in both the
presence and absence of RA (Fig. 5F). Similar results were obtained with another siRNA
that targets the distinct sequence of MKP4 (data not shown), conﬁrming the speciﬁc
effects of MKP4 siRNAs. These results taken together demonstrate that RAR signaling is
enhanced during the differentiation of CRC cells and that the enhanced RAR signaling
causes ERK inactivation, at least in part, through MKP4 upregulation to promote
differentiation.
ERK activation suppresses RAR signaling through an RIP140/HDAC-mediated
mechanism.While investigating the effects of ERK activation on Caco-2 cells, we found
that constitutively active MEK-induced ERK activation signiﬁcantly suppresses RA in-
duction of most of the RAR-dependent upregulated genes (Fig. 6A and B). ERK
activation also induced a rapid decrease in the steady-state mRNA levels of RAR (Fig.
6C). This is not a global effect on nuclear receptor-mediated gene expression as the
ligand-dependent expression of a vitamin D receptor target gene, CYP24A1, was not
suppressed; rather, it was enhanced by ERK activation (Fig. 6D). These results suggest
that ERK activation speciﬁcally suppresses RAR target gene expression. Consistent with
these results, the inhibition of ERK by U0126 treatment had the reverse effect on the
expression levels of RAR (Fig. 6E). To directly assess the effect of ERK activity on RAR
transcriptional activity, we performed a reporter assay with a construct containing
tandem repeats of an RARE (33). ERK activation by the expression of constitutively
active MEK markedly suppressed RA-stimulated RAR transcriptional activity (Fig. 6F),
and the inhibition of ERK by U0126 treatment enhanced it (Fig. 6G), indicating that ERK
activation suppresses RAR transcriptional activity. As in Caco-2 cells, ERK activation
suppressed RAR target gene expression and RAR transcriptional activity in HeLa,
HEK293, and MCF7 cells (Fig. S5A to C). These results suggest that ERK activation
antagonizes RAR target gene expression in many types of cells.
Activating mutations in K-RAS and B-RAF occur frequently in human cancers (13, 14).
Therefore, we reasoned that constitutive activation of the ERK pathway by these
mutations is responsible for the defects in RAR signaling in cancer cells. HT29 cells
harbor an activating V600E mutation in B-RAF (13) and have high basal ERK activity (Fig.
6H, right). We then found that the inhibition of ERK by U0126 treatment in HT29 cells
strongly upregulates both the basal and the RA-induced expression levels of an RAR
target gene, RARRES1 (Fig. 6H, left). These results indicate that constitutive activation of
the ERK pathway mediates the suppression of RAR transcriptional activity in cancer cells
bearing activating mutations in B-RAF. It should be noted that treatment with RA did
not decrease ERK activity in HT29 cells (Fig. 6H, right). Since induction of MKP4 by RA
was moderate compared to that in Caco-2 cells and also since ERK is constitutively and
strongly activated by a B-RAF mutation in these cells, such a moderate increase in the
MKP4 level might not be sufﬁcient to signiﬁcantly suppress ERK activity in these cells.
To address the mechanism by which ERK activation suppresses RAR signaling, we
examined the effect of ERK activation on RAR binding to the RAR promoter by using
chromatin immunoprecipitation (ChIP) experiments. To this end, we generated a cell
line stably expressing myc-tagged RAR and performed ChIP assays with an anti-myc
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antibody. The results showed that ERK activation did not inhibit the binding of RAR
to the RAR promoter (Fig. 7A). We then performed ChIP assays with antibodies to RNA
polymerase II (Pol II) and acetylated histone H4 (AcH4) to examine which step in RAR
target gene transcription is inhibited. Consistent with previous reports (2–4), RA
treatment induced H4 acetylation at the RAR promoter, and as a result, Pol II was
recruited to the promoter (Fig. 7B). Remarkably, ERK activation by expression of
RARβ
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FIG 6 ERK activation suppresses transcriptional activity of RAR. (A) Expression proﬁles of the RAR target genes in
CRC cells are shown. Cells were infected with an adenovirus expressing constitutively active MEK (caMEK) or a
control virus (vector) 12 h before treatment with DMSO or RA (100 nM). Cells were incubated for 24 h, and total
RNA was prepared and subjected to RT-PCR analysis. Each horizontal line displays the expression data for one gene,
where the ratio of the mRNA level to its level in the control cells, which were infected with a control virus (vector)
and treated with DMSO, is represented by color according to the color scale. (B) Caco-2 cells were treated as
described for panel A. The mRNA level of RAR was analyzed by RT-PCR. (C) The expression levels of the RAR
mRNA in conﬂuent Caco-2 cells infected with an adenovirus expressing constitutively active MEK (caMEK) or a
control virus (vector) were evaluated by RT-PCR. (D) Conﬂuent Caco-2 cells were infected with an adenovirus
expressing constitutively active MEK (caMEK) or a control virus (vector). At 12 h postinfection, cells were treated
with DMSO or 1,25-(OH)2-vitamin D3 (100 nM) for 24 h. Total RNA was prepared and analyzed by RT-PCR. (E) The
expression levels of the RAR mRNA in preconﬂuent Caco-2 cells treated with U0126 (10 M) or DMSO vehicle for
24 h were analyzed by RT-PCR. (F and G) Transcriptional activation of a reporter plasmid expressing luciferase under
the control of the RA-responsive elements (RARE3-Luc) was evaluated in Caco-2 cells transfected with empty
vectors or with expression plasmids for wild-type (WT) or constitutively active (CA) MEK. Cells were treated with 100
nM RA for 12 h (F) or with 10 M U0126 for 24 h (G) prior to the measurements. (H) The expression levels of the
RARRES1 mRNA in HT29 cells treated with 1 M RA and/or 10 M U0126 for 72 h were analyzed by RT-PCR
(left). HT29 and Caco-2 cells were treated with DMSO or 100 nM RA for 24 h, and cell lysates were prepared
and analyzed by immunoblotting (right). Values in panels B and D to H are means  standard errors of the
means (n  3). *, P  0.05.
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constitutively active MEK markedly decreased RA-induced H4 acetylation as well as Pol
II recruitment (Fig. 7B). We then examined the effect of the HDAC inhibitor trichostatin
A (TSA) on the ERK-induced suppression of RAR expression. The results showed that
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FIG 7 ERK activation suppresses RAR transcriptional activity through an RIP140/HDAC-mediated mechanism. (A and B)
Caco-2 cells stably expressing myc-tagged RAR, enhanced green ﬂuorescent protein (), and/or constitutively active MEK
(caMEK) were treated with DMSO or RA (100 nM) for 90 min. Chromatin fragments were prepared and subjected to ChIP
analyses with the indicated antibodies (means  standard errors of the means; panel A, n  3; panel B, n  4). (C) Caco-2
cells were infected with an adenovirus expressing constitutively active MEK or a control virus (vector) 5 h after treatment
with DMSO, RA (100 nM), and/or trichostatin A (TSA) (200 nM). Total RNA was prepared 19 h after infection and analyzed
by RT-PCR. (D) Caco-2 cells stably expressing RIP140 shRNAs or a control shRNA (shRNA targeting green ﬂuorescent protein)
were generated by using lentivirus, and transcriptional activation of the reporter plasmid (RARE3-Luc) was evaluated in
these cells. Cells were transfected with the expression plasmid for HA-RIP140 or a control plasmid. At 48 h after transfection,
cells were infected with an adenovirus expressing constitutively active MEK or a control virus (vector) and incubated for
12 h. Then, cells were treated with 100 nM RA or DMSO for 12 h prior to the measurements. (E) Caco-2 cells were infected
with lentiviruses expressing a control shRNA (shRNA targeting green ﬂuorescent protein), RIP140 shRNAs, and/or HA-
RIP140. At 72 h after lentiviral infection, cells were treated as described in the legend to Fig. 6A. Total RNA was analyzed
by qRT-PCR. Note that HA-RIP140 is expressed at a level comparable to that of endogenous RIP140 (right). (F) Lysates of
HEK293 cells transfected with expression plasmids for HA-RIP140 and/or Flag-ERK2 were subjected to immunoprecipitation
(IP) with an anti-Flag antibody (top). Caco-2 cells stably expressing HA-RIP140 at a level comparable to that of endogenous
RIP140 were generated by using lentivirus as described for panel E. Cell lysates were subjected to immunoprecipitation
with an anti-HA antibody. Values in panels C to E are means  standard errors of the means (n  3). *, P  0.05.
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activation on RAR expression (Fig. 7C). In addition, combined treatment with TSA and
RA increased RAR expression more potently than treatment with either drug alone in
HT29 cells harboring high ERK activity (Fig. S6) though expression of MKP4 was not
increased in these cells (Fig. S6) (also see Discussion). These results suggest that ERK
activation suppresses RAR target gene transcription partly by preventing RA-induced
histone acetylation in the promoter region at a step prior to Pol II recruitment.
Since classical nuclear receptor corepressors such as the nuclear receptor corepres-
sor (NCoR) and the silencing mediator of retinoid and thyroid receptor (SMRT), which
recruit HDACs to RAR, do not associate with RAR in the presence of RA (2), we thought
that other atypical corepressors might be involved in the HDAC-dependent suppression
of RAR by ERK. We then hypothesized that members of a group of ligand-dependent
corepressors that associate with and recruit HDACs to RA-bound RARs (34) could be
candidate mediators of the suppression of RAR. Among these ligand-dependent core-
pressors, RIP140 and LCoR, but not PRAME, have been shown to be expressed in
intestinal epithelial cells (35, 36). To test if RIP140 and LCoR are involved in the ERK
activation-induced suppression of RAR activity, we inhibited their expression by short
hairpin RNA (shRNA). Inhibition of LCoR expression by shRNA had essentially no effect on
the ERK activation-induced suppression of RAR activity (Fig. S5D). In contrast, inhibition of
RIP140 expression by shRNA signiﬁcantly suppressed the inhibitory effects of ERK activation
on RAR transcriptional activity and RAR expression (Fig. 7D and E). The effects of RIP140
knockdown were reversed by restoring expression of RIP140 (Fig. 7D and E), showing the
speciﬁcity of the effects. Thus, RIP140 should be required for the HDAC-dependent sup-
pression of RAR transcriptional activity by ERK. Notably, we found that HA-tagged RIP140
was coimmunoprecipitated with Flag-tagged ERK2 from lysates of HEK293 cells (Fig. 7F,
upper panel), and that endogenous ERK1/2 were coimmunoprecipitated with HA-tagged
RIP140 that was stably expressed in Caco-2 cells to the level comparable to that of
endogenous RIP140 (Fig. 7F, lower panel), demonstrating the interaction between ERK and
RIP140 in CRC cells. Collectively, these results strongly suggest that ERK activation sup-
presses RAR transcriptional activity by inducing RIP140/HDAC-mediated histone deacety-
lation at the RAR target gene promoters (also see Discussion).
DISCUSSION
The RAR and RAS/ERK signaling pathways play a crucial role in regulating prolifer-
ation and differentiation of many types of cells. As transcriptional activation of RAR
often leads to the inhibition of cell proliferation, loss of normal RAR function in the
presence of physiological levels of RA is implicated in many types of cancers (3, 4, 8, 25).
On the other hand, the activation of the ERK pathway has been shown to be required
for cell proliferation, and the constitutive activation of this pathway by the mutational
activation of K-RAS and B-RAF is associated with a diverse range of cancers (11–14). To
date, interrelationships between these signaling pathways in regulating cancer cell
fates have not been fully elucidated. Our results here indicate that RAR signaling
promotes the differentiation of CRC cells, while ERK activation suppresses it. Our
microarray analysis identiﬁed downstream target genes of RAR signaling in CRC cells.
Notably, our results have demonstrated that RAR signaling activation causes ERK
inactivation through the upregulation of MKP4, which is one of the RAR-dependently
upregulated genes. Moreover, our analyses have revealed that ERK activation sup-
presses the expression of RAR target genes through an RIP140/HDAC-mediated mech-
anism. Taken together, our results have revealed novel antagonistic interactions be-
tween the RAS/ERK and RAR signaling pathways.
It should be noted that treatment with pharmacological doses of retinoids, which
results in the activation of RAR signaling, has been considered a promising strategy for
cancer therapy and prevention (3, 4, 8). However, how retinoids achieve these biolog-
ical effects has not been fully elucidated. Rather surprisingly, our microarray analyses
revealed that only a small number of genes are signiﬁcantly upregulated by RAR
signaling in CRC cells. Identiﬁcation of the RAR-dependent upregulated genes here
would facilitate our understanding of the molecular mechanisms of action of retinoids
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in cancer therapy and prevention. An important example is the present ﬁnding that
RAR signaling induces MKP4 expression to inactivate ERK as the deregulated activation
of ERK is among general mechanisms for cancer.
While many reports have shown the beneﬁcial clinical effects of retinoids, accumu-
lating evidence suggests that solid tumors acquire intrinsic resistance to retinoids
during carcinogenesis, which has prevented retinoids from further application (4, 8).
Strategies to overcome this resistance have long been discussed. Our ﬁnding that ERK
activation, which is often caused by RAF or RAS mutations in cancer cells, suppresses
RAR transcriptional activity through an RIP140/HDAC-mediated mechanism might pro-
vide a clue to the elucidation of underlying mechanisms of the retinoid resistance. In
line with this idea, combinatorial treatment with RA and an HDAC inhibitor (TSA)
restored expression of RAR in HT29 colorectal cancer cells, in which ERK is constitu-
tively activated by a B-RAF mutation (see Fig. S6 in the supplemental material). On the
other hand, however, the expression level of MKP4 was not increased signiﬁcantly by
combinatorial treatment with RA and TSA (Fig. S6). Since the contribution of the
RIP140/HDAC-mediated mechanism to ERK activation-induced suppression of RAR
activity is partial (as shown by partial recovery of RAR activity after RIP140 knockdown)
(Fig. 7D and E), other mechanisms might suppress expression of MKP4 in HT29 cells.
Elucidation and pharmacological inhibition of such mechanisms would be the next
important challenge in future studies. Notably, overexpression of PRAME, another
ligand-dependent corepressor of RAR, has also been implicated in retinoid resistance of
cancer cells (35). Based on our results and those of other investigators, it can be
speculated that cancer cells often escape from the tumor-suppressive effect of RAR
signaling by promoting the function of these ligand-dependent corepressors. An
important difference between RIP140 and PRAME is that the function of RIP140 appears
to be regulated posttranslationally by ERK activation whereas that of PRAME is regu-
lated at the transcription level. Indeed, previous studies have shown that ERK phos-
phorylates RIP140 on Thr202/Thr207, which facilitates the transcription-suppressing
activity of RIP140 by promoting its interaction with HDAC3 and CDK8-G9a (37, 38).
Given that both HDACs and RIP140 are required for ERK activation-induced suppression
of RAR and that ERK interacts with RIP140 in CRC cells, it is plausible that ERK activation
confers resistance to retinoids on CRC cells by enhancing the function of RIP140.
In summary, our results identify novel antagonistic interactions between RAR and ERK
signaling in CRC cells. These ﬁndings provide crucial insights into the mechanism of action
of retinoids in cancer treatment and the retinoid resistance of cancer cells, two important
issues related to the clinical use of retinoids. More generally, the elucidation of the
mechanisms for novel interactions between the two important signaling pathways would
shed light on the molecular bases for many physiological and pathological processes.
MATERIALS AND METHODS
Cell culture. Caco-2, HT29, HeLa, and HEK293 cells were obtained from the American Type Culture
Collection and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 2 mM glutamine, and antibiotics (100 U/ml of penicillin and 0.2 mg/ml of
kanamycin). For spontaneous differentiation experiments, the time when Caco-2 cells ﬁrst reached
conﬂuence was designated day 0, and cells were treated with RA, LE540, and retinol from this time point.
Medium was replaced daily during the experiments. For siRNA experiments, Caco-2 cells were transfected
with a control siRNA or siRNAs that target human MKP4 (Invitrogen). Transfection of siRNAs was
performed with siPORT Amine transfection reagent (Ambion).
Plasmids, antibodies, and reagents. To obtain the RARE3-Luc reporter plasmid, a trimer of the
RA-responsive element (RARE3) in the RAR gene was inserted into the pGL3 luciferase (Luc) reporter
vector (Promega) as described previously (33). For MKP4 promoter analysis, a region spanning 200
to141 in reference to the transcriptional start site (ENST00000342782; Database of Transcriptional Start
Sites [DBTSS]) of the MKP4 promoter, which contains an inverted direct repeat separated by 1 bp (DR1)
(wild-type [WT], 5=TGGCCTCTGCCCC3=; mutant [4CG], 5=TGGGGTCTGCGGC3=), was inserted into the pGL3
luciferase reporter vector (Promega). Expression plasmids for wild-type and constitutively active MEK
(LA-SDSE) have been described previously (39). To construct expression plasmids for RAR and RXR,
cDNAs of human RAR and RXR were PCR ampliﬁed and cloned into a pcDNA3 vector (Invitrogen).
Antibodies speciﬁc for RAR (Santa Cruz), MKP4 (Santa Cruz), ERK1/2 (Santa Cruz), phospho-ERK1/2 (Cell
Signaling), p38 (Santa Cruz), phospho-p38 (Cell Signaling), MEK1 (Santa Cruz), phospho-MEK1 (Cell
Signaling), HA (Covance), Flag (Sigma), and -tubulin (Sigma) were used for immunoblotting. U0126 was
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purchased from Promega. All-trans-retinoic acid and all-trans-retinol were purchased from Sigma. LE540
was purchased from Wako Pure Chemical. Retinol was stocked in ethanol, and the other drugs were
stocked in dimethyl sulfoxide (DMSO).
Luciferase assay. Caco-2 cells (1  105 cells/well) were seeded in 12-well plates 24 h before
transfection. LipofectAMINE Plus transfection reagent (Invitrogen) was used according to the manufac-
turer’s instructions. Cells were transfected with 0.3 g of RARE3-Luc reporter plasmid and 1 g of test
plasmid and incubated for 24 h. Cells were treated with 100 nM RA for 12 h or 10 M U0126 for 24 h
prior to the measurement. For MKP4 promoter analysis, cells were transfected with 0.2 g of pGL3
reporter vector containing a wild-type (WT) or mutated (4CG) DR1 element of the MKP4 promoter and
0.3 g of expression plasmids for RAR and RXR and incubated for 24 h. Cells were then treated with
1 M RA or Ch55 for 36 h prior to the measurement. Luciferase activity in cell lysates was measured by
using a luciferase assay system (Promega). We normalized the relative luciferase activity to the activity
of coexpressed -galactosidase.
RT-PCR analysis. Total RNA was extracted by using an RNeasy minikit (Qiagen) according to the
manufacturer’s instructions and was then reverse transcribed into cDNA by Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Invitrogen) with oligonucleotide random hexamers.
Prepared cDNA was puriﬁed and subjected to quantitative PCR analysis by using a Light Cycler
(Roche Diagnostics) or ABI 7300 Real Time PCR System (Applied Biosystems) with a SYBR green PCR
kit (Applied Biosystems). Each value obtained was normalized to that of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
DNA pulldown and ChIP assays. For DNA pulldown experiments, cell lysates were incubated with
2 g of biotinylated double-stranded oligonucleotides (equivalent to the MKP4 promoter region [200
to 141] containing the WT or mutated [4CG] DR1) and 5 g of poly(dI-dC) at 4°C for 1 h in binding
buffer (20 mM HEPES [pH 7.8], 100 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10 mM Na4P2O4, 1% NP-40, and
10% glycerol). DNA-bound proteins were collected with streptavidin-agarose beads (Invitrogen) for
1 h, washed extensively with binding buffer, and resuspended in protein loading buffer. The samples
were analyzed by immunoblotting. Chromatin immunoprecipitation (ChIP) assays were performed
using a ChIP-IT Express kit (Active Motif) according to the manufacturer’s instructions. Brieﬂy, cells
were ﬁxed with 1% formaldehyde for 10 min at room temperature, and then chromatin was prepared
and sonicated extensively. Chromatin fragments were immunoprecipitated with anti-RNA polymer-
ase II (Covance), anti-myc (Santa Cruz), and anti-acetylated H4 antibodies (Upstate). Puriﬁed rabbit
IgG (Santa Cruz) was used as a control. Immunoprecipitated DNA and input DNA were analyzed by
quantitative PCR.
Microarray analysis. For microarray analysis, we performed two independent series of experi-
ments. Caco-2 cells were treated with 100 nM RA or DMSO vehicle for 24 h, and total RNA was
extracted by using an RNeasy minikit (Qiagen). Synthesis of cDNA, in vitro transcription and biotin
labeling of cRNA, and hybridization to the human genome U133 Plus 2.0 array (Affymetrix) were
performed according to Affymetrix protocols. Hybridized arrays were scanned using an Affymetrix
GeneChip scanner. Images from scanned chips were processed by using the default settings of
GeneChip Operating Software (GCOS), version 1.4. The CELL ﬁles created by GCOS were imported
into the GeneSpring GX, version 7.3 (Agilent Technologies), microarray analysis software for statis-
tical analysis and presentation of the expression proﬁles and average-expression proﬁles. Probe
intensities were normalized, and expression signals of all genes (probe sets) were calculated using
GeneChip robust multiarray averaging (GCRMA). The genes whose signal intensities were extremely
low were excluded from further analysis. RA-dependently upregulated genes were identiﬁed by
statistical analysis and fold change values. Statistical analysis was performed by one-way analysis of
variance (ANOVA) with a Benjamini-Hochberg false discovery rate (equal to 0.05) multiple testing
correction followed by Tukey’s post hoc tests.
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